A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

December 7, 2021

Study Completion Date

March 23, 2022

Conditions
Venous Leg Ulcer
Interventions
DRUG

EscharEx (5% EX-02 formulation)

Active arm

DRUG

Gel Vehicle

Control arm

DRUG

Non-surgical standard of care (NSSOC)

Santyl (Enzymatic debridement) or commercially approved Hydrogel

Trial Locations (22)

1211

Hopitaux Universitaires de Geneva, Geneva

10025

Mount Sinai St. Luke's Hospital, New York

11501

NYU Winthrop Hospital, Mineola

11794

Stony Brook University Hospital, Stony Brook

20007

Medstar Health Georgetown University, Washington D.C.

33126

INTEGRAL - Clinical Trials Solutions, Doral

33134

C & R Research Services USA, Inc, Coral Gables

33136

University of Miami, Miami

33169

Barry University Clinical Research, Miami Beach

53221

AZH Wound Center, Milwaukee

60611

Northwestern University, Chicago

89119

Advanced Foot & Ankle Center, Las Vegas

90057

Felix Sigal. D.P.M, PC, Los Angeles

92009

ILD Research Center, Carlsbad

93710

Limb Preservation Platform, Inc., Fresno

94063

Stanford, Redwood City

94115

Center for Clinical Research Inc., San Francisco

02114-2621

Massachusetts General Hospital, Boston

02118

Boston Medical Center/Boston University Medical Center, Boston

02189

South Shore Health System, Center for Wound Healing, Weymouth

07901

Atlantic Health System - Overlook Wound Care Center, Summit

08753

Bey Lea Ambulatory Surgical Center, Toms River

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MediWound Ltd

INDUSTRY